Bio Usawa and Sartorius Stedim Biotech Partner to Advance Biopharmaceutical Manufacturing in Africa
Wednesday, July 30, 2025
Bio Usawa Biotechnology Ltd, an African biotechnology company, has partnered with Sartorius Stedim Biotech, a global biopharmaceutical manufacturing solutions provider, to strengthen Africa’s biopharmaceutical sector. This collaboration aims to improve access to affordable, high-quality monoclonal antibodies in Sub-Saharan Africa to help address a growing range of health challenges, including cancer, diabetes-related eye conditions, infectious diseases, and autoimmune disorders.
The partnership will also support workforce development, process innovation, and technology transfer to enhance local capacity in the region.
As part of the agreement, both companies will work together on research and development, focusing on biosimilar cell lines suited to African healthcare needs. Training programmes will be introduced to build local expertise in biopharmaceutical production, and Sartorius Stedim Biotech will provide advanced bioprocessing tools and materials for upstream and downstream manufacturing.
The collaboration will also include process optimisation and analytical support to help ensure efficient, scalable, and quality-compliant manufacturing processes. Sartorius Stedim Biotech’s knowledge in quality control and analytical testing will play a key role in strengthening Bio Usawa’s capabilities in product quality assurance.
Through this initiative, Bio Usawa will make use of its leadership team’s experience in product development, clinical trials, and regulatory strategy across both mature and emerging markets. The aim is to drive innovation that is specifically tailored to Africa’s healthcare needs.
This partnership is seen as a significant step toward improving healthcare access and establishing a sustainable biopharmaceutical manufacturing base in Africa, with a focus on long-term health resilience and self-sufficiency.
Source: globenewswire.com
